A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 358
- 试验地点
- 15
- 主要终点
- Graft-versus-host disease-free, relapse-free survival (GRFS)
研究概览
简要总结
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination.
Participants will:
- Receive the standard or new drug combination after transplant
- Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients
- Take surveys about physical and emotional well-being
- Give blood and stool samples.
详细描述
This platform protocol will evaluate the safety and efficacy of post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GVHD) prophylaxis after mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT). Participants with malignant hematologic diseases eligible per inclusion criteria, receiving MMUD peripheral blood stem cells (PBSCs) after myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) will be eligible to be enrolled by participating transplant centers. The platform protocol will estimate endpoints and provide a comparator arm for investigational interventional arms (ISAs).
Two investigational ISAs are part of the platform protocol - ACCEL-001 and ACCEL-002. The ISAs describe the specific features of the intervention being studied and treatment of participants assigned to that intervention, the specific target population, sample size required based on comparison to the control arm, specific study objectives, statistical methods for evaluating the interventions, and other specific intervention-related information and assessments. Additional ISAs may be added or closed throughout the lifetime of the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •, MAC RECIPIENTS:
- •Age 18 to < 66 years (chemotherapy-based conditioning) or < 61 years (TBI-based conditioning) at the time of signing informed consent
- •Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Planned MAC regimen (see Table 8 in Section 7.4 for allowed MAC regimens)
- •Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35
- •Product planned for infusion is MMUD T-cell replete PBSC as allograft
- •HCT-CI < 5 (Appendix H - Hematopoietic Cell Transplant Comorbidity Index Scoring). The presence of prior malignancy will not be used to calculate HCT-CI for this trial, to allow for the inclusion of patients with secondary or therapy-related AML or MDS.
- •One of the following diagnoses:
- •AML, ALL, or other acute leukemia in first remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
- •Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% vs 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
- •Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results
- •Estimated creatinine clearance ≥ 45mL/min calculated by equation
- •Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥ 50% and forced expiratory volume in first second (FEV1) predicted ≥ 50% based on most recent PFT results
- •Liver function acceptable per local institutional guidelines
- •KPS of ≥ 70% (Appendix I - Performance Status)
- •Inclusion Criteria, RIC/NMA RECIPIENTS:
- •Age ≥ 18 years at the time of signing informed consent
- •Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Planned NMA/RIC regimen (see
- •Table 9 in Section 7.4 for allowed NMA/RIC regimens)
- •Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35
- •Product planned for infusion is MMUD T-cell replete PBSC allograft
- •One of the following diagnoses:
- •Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with < 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
- •Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% vs 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
- •Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation.
- •Higher-risk chronic myelomonocytic leukemia (CMML) according to CMML-specific prognostic scoring system or high-risk MDS/myeloproliferative neoplasms (MPN) not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment.
- •Patients with lymphoma with chemosensitive disease at the time of transplantation.
- •Patients with primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera or MDS with grade 4 fibrosis.
- •Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure
- •Estimated creatinine clearance ≥ 45mL/min calculated by equation
- •Pulmonary function: DLCO corrected for hemoglobin ≥ 50% and FEV1 predicted ≥ 50% based on most recent PFT results
- •Liver function acceptable per local institutional guidelines
- •KPS of ≥ 60% (Appendix I - Performance Status)
排除标准
- •Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available
- •Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
- •Subjects with a prior allogeneic transplant
- •Subjects with an autologous transplant within the past 3 months
- •Subjects who are breastfeeding or pregnant
- •Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen
- •Concurrent enrollment on a GVHD prevention clinical trial
- •Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant
- •Patients who are HIV-positive with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well-controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled.
研究组 & 干预措施
Control/SOC
Shared comparator control group
干预措施: Conditioning Regimen A (Drug)
Control/SOC
Shared comparator control group
干预措施: Conditioning Regimen B (Drug)
Control/SOC
Shared comparator control group
干预措施: Conditioning Regimen C (Drug)
Control/SOC
Shared comparator control group
干预措施: Conditioning Regimen D (Drug)
Control/SOC
Shared comparator control group
干预措施: Conditioning Regimen E (Drug)
Control/SOC
Shared comparator control group
干预措施: Hematopoietic Cell Transplantation (Procedure)
Control/SOC
Shared comparator control group
干预措施: PTCy (50 mg/kg D3, D4) (Drug)
Control/SOC
Shared comparator control group
干预措施: Post-transplant Tacrolimus (Drug)
Control/SOC
Shared comparator control group
干预措施: Post-transplant Mycophenolate mofetil (Drug)
Control/SOC
Shared comparator control group
干预措施: Study treatment compliance (Other)
Control/SOC
Shared comparator control group
干预措施: Prohibited Concomitant Therapy (Other)
Control/SOC
Shared comparator control group
干预措施: Permitted Concomitant Therapy (Other)
ACCEL-001
Intervention 1
干预措施: Permitted Concomitant Therapy (Other)
ACCEL-001
Intervention 1
干预措施: Conditioning Regimen A (Drug)
ACCEL-001
Intervention 1
干预措施: Conditioning Regimen B (Drug)
ACCEL-001
Intervention 1
干预措施: Conditioning Regimen C (Drug)
ACCEL-001
Intervention 1
干预措施: Conditioning Regimen D (Drug)
ACCEL-001
Intervention 1
干预措施: Conditioning Regimen E (Drug)
ACCEL-001
Intervention 1
干预措施: Hematopoietic Cell Transplantation (Procedure)
ACCEL-001
Intervention 1
干预措施: PTCy (25 mg/kg D3, D4) (Drug)
ACCEL-001
Intervention 1
干预措施: Post-transplant Tacrolimus (Drug)
ACCEL-001
Intervention 1
干预措施: Post-transplant Abatacept (Drug)
ACCEL-001
Intervention 1
干预措施: Study treatment compliance (Other)
ACCEL-001
Intervention 1
干预措施: Prohibited Concomitant Therapy (Other)
ACCEL-002
Intervention 2
干预措施: Conditioning Regimen A (Drug)
ACCEL-002
Intervention 2
干预措施: Conditioning Regimen B (Drug)
ACCEL-002
Intervention 2
干预措施: Conditioning Regimen C (Drug)
ACCEL-002
Intervention 2
干预措施: Conditioning Regimen D (Drug)
ACCEL-002
Intervention 2
干预措施: Conditioning Regimen E (Drug)
ACCEL-002
Intervention 2
干预措施: Hematopoietic Cell Transplantation (Procedure)
ACCEL-002
Intervention 2
干预措施: PTCy (25 mg/kg D3, D4) (Drug)
ACCEL-002
Intervention 2
干预措施: Post-transplant Tacrolimus (Drug)
ACCEL-002
Intervention 2
干预措施: Post-transplant Mycophenolate mofetil (Drug)
ACCEL-002
Intervention 2
干预措施: Post-transplant Ruxolitinib (Drug)
ACCEL-002
Intervention 2
干预措施: Study treatment compliance (Other)
ACCEL-002
Intervention 2
干预措施: Prohibited Concomitant Therapy (Other)
ACCEL-002
Intervention 2
干预措施: Permitted Concomitant Therapy (Other)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Growth Factors (Drug)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Blood Products (Procedure)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Infection Prophylaxis (Other)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Intravenous immune globulin (IVIG) (Other)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Seizure prophylaxis (Drug)
Control/SOC
Shared comparator control group
干预措施: Supportive Care: Monitoring and management of CRS (Other)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Growth Factors (Drug)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Blood Products (Procedure)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Lipid elevations (Other)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Infection Prophylaxis (Other)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Intravenous immune globulin (IVIG) (Other)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Seizure prophylaxis (Drug)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Monitoring and management of CRS (Other)
ACCEL-001
Intervention 1
干预措施: Supportive Care: Prophylaxis against infections (Other)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Growth Factors (Drug)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Blood Products (Procedure)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Infection Prophylaxis (Other)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Intravenous immune globulin (IVIG) (Other)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Seizure prophylaxis (Drug)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Monitoring and management of CRS (Other)
ACCEL-002
Intervention 2
干预措施: Supportive Care: Prophylaxis against infections (Drug)
结局指标
主要结局
Graft-versus-host disease-free, relapse-free survival (GRFS)
时间窗: 1 year post-HCT
To compare GRFS following transplantation of a PBSC product from a MMUD between standard-of-care PTCy-based GVHD prophylaxis (the control arm) and the combination of reduced-dose PTCy, ruxolitinib, tacrolimus, and MMF.
次要结局
- Graft-versus-host disease-free survival (GFS)(1 year post-HCT)
- Non-relapse mortality (NRM)(1 year post-HCT)
- Cumulative incidence of relapse and disease progression(1 year post-HCT)
- Cumulative incidence of neutrophil engraftment(1 year post-HCT)
- Infection-free survival (IFS)(1 year post-HCT)
- Overall survival (OS)(1 year post-HCT)
- Progression-free survival (PFS)(1 year post-HCT)
- Cumulative incidence of platelet engraftment(1 year post-HCT)
- Primary graft failure (PGS) and secondary graft failure (SGF)(1 year post-HCT)
- Cumulative incidence of aGVHD(1 year post-HCT)
- Cumulative incidence of cGVHD(1 year post-HCT)
- Incidence of ≥ grade 2 infections(1 year post-HCT)
- Donor cell engraftment(1 year post-HCT)
- Incidence of cytokine release syndrome (CRS)(1 year post-HCT)